Cutera (NASDAQ:CUTR) was upgraded by Zacks Investment Research from a “strong sell” rating to a “hold” rating in a research report issued on Wednesday.
According to Zacks, “Cutera Inc designs, develops, manufactures and markets the CoolGlide family of products for use in laser and other light-based aesthetic applications. The original CoolGlide CV provides permanent hair reduction on all skin types. The second generation CoolGlide Excel incorporated features that added the capability to treat a variety of vascular lesions, which include facial telangiectasia, spider and reticular leg veins. The CoolGlide Vantage added non-ablative skin therapy to the range of applications offered by the system. “
Other analysts also recently issued research reports about the stock. ValuEngine raised shares of Cutera from a “hold” rating to a “buy” rating in a report on Thursday, November 1st. Sidoti set a $50.00 target price on shares of Cutera and gave the stock a “buy” rating in a report on Friday, October 5th. BidaskClub downgraded shares of Cutera from a “buy” rating to a “hold” rating in a report on Thursday, September 20th. Stifel Nicolaus reduced their target price on shares of Cutera from $55.00 to $45.00 and set a “hold” rating for the company in a report on Wednesday, August 8th. Finally, Stephens reduced their target price on shares of Cutera from $40.00 to $24.94 and set a “sell” rating for the company in a report on Friday, October 5th. One research analyst has rated the stock with a sell rating, three have assigned a hold rating and three have given a buy rating to the company. The company presently has an average rating of “Hold” and an average target price of $39.24.
Cutera stock opened at $18.82 on Wednesday. The stock has a market cap of $263.89 million, a PE ratio of 24.44 and a beta of 0.87. Cutera has a fifty-two week low of $17.94 and a fifty-two week high of $56.05.
Cutera (NASDAQ:CUTR) last announced its earnings results on Tuesday, November 6th. The medical device company reported $0.11 EPS for the quarter, topping the consensus estimate of $0.03 by $0.08. The business had revenue of $40.60 million during the quarter, compared to the consensus estimate of $40.03 million. Cutera had a net margin of 11.16% and a negative return on equity of 0.50%. Cutera’s revenue was up 6.4% compared to the same quarter last year. During the same quarter in the previous year, the firm posted $0.42 EPS. Research analysts predict that Cutera will post -0.29 earnings per share for the current fiscal year.
Hedge funds have recently made changes to their positions in the stock. Piedmont Investment Advisors LLC bought a new stake in Cutera in the 2nd quarter valued at about $128,000. SG Americas Securities LLC bought a new stake in Cutera in the 2nd quarter valued at about $154,000. United Services Automobile Association bought a new stake in Cutera in the 2nd quarter valued at about $208,000. Assenagon Asset Management S.A. bought a new stake in Cutera in the 3rd quarter valued at about $263,000. Finally, MetLife Investment Advisors LLC boosted its holdings in Cutera by 54.6% in the 3rd quarter. MetLife Investment Advisors LLC now owns 10,424 shares of the medical device company’s stock valued at $339,000 after purchasing an additional 3,680 shares during the period.
Cutera Company Profile
Cutera, Inc, a medical device company, designs, develops, manufactures, markets, and services laser and other energy based aesthetics systems worldwide. The company offers enlighten platform, a laser system that is used for tattoo removal, as well as for the treatment of benign pigmented lesions; excel HR platform, a hair removal solution for various skin types; and truSculpt, a high-powered radio frequency platform designed for deep tissue heating.
Read More: Market Capitalization
Get a free copy of the Zacks research report on Cutera (CUTR)
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Cutera Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cutera and related companies with MarketBeat.com's FREE daily email newsletter.